Januvia Lawsuits Move Forward in Federal Court, with Scheduling of Initial Conference in Januvia Pancreatic Cancer Litigation, Bernstein Liebhard LLP Reports

The Firm is investigating Januvia lawsuits on behalf of patients who were diagnosed with pancreatic cancer after taking Januvia to treat Type 2 diabetes.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
We are pleased to see this litigation moving forward, as we receive inquiries on a regular basis from patients who are concerned about the alleged link between Januvia and pancreatic cancer.

New York, New York (PRWEB) September 30, 2013

The federal multidistrict litigation established in California federal court for Januvia lawsuits (http://www.januvialawsuithelp.com) and other product liability claims involving a class of Type 2 diabetes drugs called incretin mimetics has begun to move forward, Bernstein Liebhard LLP reports. According to an Order issued on September 11, 2013 in the U.S. District Court, Southern District of California, the proceeding’s Initial Conference has been scheduled for October 17th. All of the lawsuits pending in the litigation allege an association between incretin mimetics, including Januvia, and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“We are pleased to see this litigation moving forward, as we receive inquiries on a regular basis from patients who are concerned about the alleged link between Januvia and pancreatic cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal evaluations to alleged victims of Januvia pancreatic cancer, as well as pancreatitis and thyroid cancer.

Januvia Pancreatic Cancer Allegations

According to court documents, at least 60 lawsuits have already been filed in the federal incretin mimetics litigation since it was established by the U.S. Judicial Panel on Multidistrict Litigation last month. All of the Januvia lawsuits pending in the proceeding claim that Merck & Co. failed to provide doctors and patients with adequate warnings regarding a potential link between Januvia and pancreatic cancer.

In recent years, Januvia and other incretin mimetics have been the subject of safety concerns, amid a growing body of evidence that indicates these medications could have harmful effects on the pancreas. In 2009, the U.S. Food & Drug Administration (FDA) ordered changes to the Januvia label after the agency became aware of 88 instances where Januvia patients had developed acute pancreatitis.* In 2011, a Gastroenterology study reported Januvia appeared to increase the risk of pancreatitis and pancreatic cancer, while two cases of thyroid cancer were
also reported in the patients who took Januvia.**

Most recently, the FDA reported this past March that it was reviewing the entire incretin mimetics class after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. The FDA has since said that it has been unable to confirm such a link, but it continues to review the drugs. This past June, a British Medical Journal investigation revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.****

Januvia patients who developed pancreatic cancer, thyroid cancer or pancreatitis may be eligible to file a Januvia lawsuit seeking compensation for medical bills, lost wages, pain and suffering and more. Click Here to learn more about contacting a Januvia lawyer at Bernstein Liebhard LLP. For more information about obtaining a free case review, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**http://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs, Pharmalot, July 31, 2013
****bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.januvialawsuithelp.com